Neogen wins trademark lawsuit
July 30, 2003
CONTACT: Richard R. Current, Vice President & CFO, 517-372-9200 |
LANSING, Mich., July 30, 2003 — Neogen Corporation (Nasdaq: NEOG) announced today that a federal court has ruled in its favor in a trademark infringement lawsuit against Neo Gen Screening, a Pennsylvania-based company.
In his ruling following the trial, Judge Robert Holmes Bell of the U.S. District Court for the Western District of Michigan granted Neogen Corporation a permanent injunction and ordered Neo Gen Screening to discontinue the use of the sequence of letters “N E O G E N”. In addition to ruling that Neo Gen Screening was infringing Neogen Corporation’s trademark, the federal court also awarded Neogen Corporation its attorney fees in connection with bringing the lawsuit.
Neogen Corporation was founded in 1982 and owns the federally registered trademark to “Neogen®”. Its product line includes over 150 diagnostic test kits, including those for the detection of metabolic disorders. Neo Gen Screening began operations in 1994 and its laboratory provides screening for metabolic disorders.
Neogen Corporation is a market leader in developing and marketing products and services dedicated to food and animal safety, and life sciences. The Company’s Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, metabolic disorders, food allergens, drug residues, plant diseases and sanitation concerns. Neogen’s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, and life science tests and reagents.
Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s most recently filed Form 10-K.